Stemline Therapeutics, Inc.
STML
STML was delisted on the 9th of June, 2020.
82 hedge funds and large institutions have $310M invested in Stemline Therapeutics, Inc. in 2018 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 31 increasing their positions, 18 reducing their positions, and 13 closing their positions.
72% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 18
32% more capital invested
Capital invested by funds: $235M → $310M (+$75M)
23% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 13
3% more funds holding
Funds holding: 80 → 82 (+2)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
86% less call options, than puts
Call options by funds: $296K | Put options by funds: $2.15M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$20.7M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$9.12M |
| 3 |
State Street
Boston,
Massachusetts
|
+$8.21M |
| 4 |
ACA
Avoro Capital Advisors
New York
|
+$8.17M |
| 5 |
NC
Nexthera Capital
New York
|
+$8.16M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
-$5.39M |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$4.68M |
| 3 |
Millennium Management
New York
|
-$3.58M |
| 4 |
JP Morgan Chase
New York
|
-$733K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$570K |
STML Hedge Fund Activity: Q1 2018 in Review
82 of the 4,373 institutional investors tracked by Wall St. Rank reported a position in Stemline Therapeutics, Inc. (STML) for Q1 2018, worth a combined $310M — up 32% from $235M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new STML positions and 13 closed out — a net gain of 3 holders — while 31 added to existing stakes and 18 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $20.7M. The largest seller was Baker Bros. Advisors, cutting an estimated $5.39M.
- 82 institutional investors held Stemline Therapeutics, Inc. (STML) as of Q1 2018, up from 80 in Q4 2017.
- Funds reported $310M of Stemline Therapeutics, Inc. stock for Q1 2018, up 32% quarter-over-quarter.
- 16 funds opened new Stemline Therapeutics, Inc. positions in Q1 2018 and 13 closed out, a net change of +3 holders.
- The largest Stemline Therapeutics, Inc. buyer in Q1 2018 was Fidelity Investments, an estimated $20.7M added.
- The largest Stemline Therapeutics, Inc. seller in Q1 2018 was Baker Bros. Advisors, an estimated $5.39M sold.
Based on aggregated 13F filings for Q1 2018.